--- title: "HC Wainwright Has Negative Outlook for SPTX FY2026 Earnings" type: "News" locale: "en" url: "https://longbridge.com/en/news/295102115.md" description: "HC Wainwright lowered its FY2026 EPS estimate for Seaport Therapeutics to ($4.09) from ($3.25), citing a negative outlook, while maintaining a 'Buy' rating and $50 price target. Other analysts have issued mixed ratings, including 'outperform', 'overweight', 'sell', and 'market perform'. The consensus rating is 'Hold' with a $38.40 target. Seaport recently reported Q1 2027 earnings of ($1.78), missing estimates." datetime: "2026-08-06T11:43:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295102115.md) - [en](https://longbridge.com/en/news/295102115.md) - [zh-HK](https://longbridge.com/zh-HK/news/295102115.md) generator: "portal-rs" --- # HC Wainwright Has Negative Outlook for SPTX FY2026 Earnings Seaport Therapeutics, Inc. (NASDAQ:SPTX - Free Report) - HC Wainwright lowered their FY2026 earnings per share estimates for Seaport Therapeutics in a research report issued on Tuesday, August 4th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($4.09) for the year, down from their prior estimate of ($3.25). HC Wainwright has a "Buy" rating and a $50.00 price objective on the stock. HC Wainwright also issued estimates for Seaport Therapeutics' Q1 2027 earnings at ($0.62) EPS, Q3 2027 earnings at ($0.67) EPS and FY2027 earnings at ($2.62) EPS. Get **Seaport Therapeutics** alerts: Several other analysts have also recently commented on the company. Leerink Partners began coverage on Seaport Therapeutics in a research report on Tuesday, May 26th. They issued an "outperform" rating and a $35.00 target price on the stock. Seaport Research Partners set a $50.00 price target on Seaport Therapeutics in a research report on Wednesday, July 15th. JPMorgan Chase & Co. initiated coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They issued an "overweight" rating and a $42.00 price target for the company. UBS Group lowered Seaport Therapeutics to a "sell" rating in a report on Tuesday, June 9th. Finally, BNP Paribas Exane downgraded shares of Seaport Therapeutics to a "market perform" rating in a report on Tuesday, May 26th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $38.40. **View Our Latest Report on Seaport Therapeutics** ## Seaport Therapeutics Stock Performance Shares of NASDAQ:SPTX opened at $22.34 on Thursday. The firm has a 50-day moving average price of $19.52. The company has a market cap of $1.20 billion and a P/E ratio of -2.16. Seaport Therapeutics has a fifty-two week low of $14.85 and a fifty-two week high of $23.00. Seaport Therapeutics (NASDAQ:SPTX - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($1.07). ## Insider Activity In related news, Director Robert J. Hombach acquired 13,000 shares of the business's stock in a transaction dated Monday, June 22nd. The stock was bought at an average price of $18.14 per share, for a total transaction of $235,820.00. Following the transaction, the director owned 13,000 shares of the company's stock, valued at approximately $235,820. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Seaport Therapeutics, Inc is a healthcare company in the Pharmaceuticals industry. ## See Also - Five stocks we like better than Seaport Therapeutics - Why Analysts Are Bullish on a Stock That's Down 20% - SpaceX: Love the Company, But the Stock Is a Harder Call - Ulta's Growth Is Real, But So Are the Risks - BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Seaport Therapeutics Right Now? Before you consider Seaport Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seaport Therapeutics wasn't on the list. While Seaport Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [SPTX.US](https://longbridge.com/en/quote/SPTX.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [BNPQY.US](https://longbridge.com/en/quote/BNPQY.US.md) - [ULTA.US](https://longbridge.com/en/quote/ULTA.US.md) - [BWXT.US](https://longbridge.com/en/quote/BWXT.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) ## Related News & Research - [Is Wall Street Bullish or Bearish on Alexandria Real Estate Stock?](https://longbridge.com/en/news/296925778.md) - [Sysco announces Q3 2026 distribution of R$ 0.32 per unit, payable Oct. 29](https://longbridge.com/en/news/296782340.md) - [Is Wall Street Bullish or Bearish on BXP Stock?](https://longbridge.com/en/news/296784550.md) - [NiSource declares Q3 2026 distribution of R$ 1.05 per unit, payable Aug. 26](https://longbridge.com/en/news/296784415.md) - [Gogoro Q2 FY26 IFRS net loss narrows to $4.9 million; revenue rises 7.3% year-over-year to $70.6 million](https://longbridge.com/en/news/296775396.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**